Celgene Corp (CELG):企業の財務・戦略的SWOT分析

◆英語タイトル:Celgene Corp (CELG) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15301
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Celgene Corp (CELG) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Celgene Corp (Celgene) is an integrated global biopharmaceutical company that carries out the research, development, manufacture and marketing of novel therapies to treat cancer and immune-inflammatory related diseases through gene and protein regulation. Its product portfolio includes Vidaza (azacitidine) for the treatment of myelodysplastic syndromes (MDS); Revlimid (lenalidomide), Pomalyst (pomalidomide) and Thalomid (thalidomide) for the treatment of multiple myeloma; Abraxane (paclitaxel albumin-bound particles for injectable suspension) for various types of cancers; Otezla (apremilast) for psoriatic arthritis; and Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL) and Peripheral T-cell lymphoma (PTCL). The company also has several products in various stages of development for the treatment of hematological and solid tumor cancers. It has manufacturing facilities in Boudry and Zofingen in Switzerland; and Arizona, the US. The company sells its products through own sales organizations and distributors in the Americas, Europe, the Middle-East and Asia-Pacific. Celgene is headquartered in Summit, New Jersey, the US.

Celgene Corp Key Recent Developments

Mar 11,2019 Celgene files for EU approval of ozanimod in relapsingremitting MS with US resubmission on track httpswww.firstwordpharma.comnode1628754Â $CELG
Mar 11,2019 Celgene Submits Application to EMA for Ozanimod for the Treatment of RelapsingRemitting Multiple Sclerosis
Mar 04,2019 Adagene announces a platform evaluation of the dynamic precision library with Celgene
Mar 01,2019 BMS faces shareholder opposition to $74bn Celgene acquisition

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Celgene Corp – Key Facts
Celgene Corp – Key Employees
Celgene Corp – Key Employee Biographies
Celgene Corp – Major Products and Services
Celgene Corp – History
Celgene Corp – Company Statement
Celgene Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Celgene Corp – Business Description
Product Category: Abraxane
Overview
Performance
Product Category: Azacitidine for injection
Overview
Performance
Product Category: Idhifa
Overview
Performance
Product Category: Istodax
Overview
Performance
Product Category: Otezla
Overview
Performance
Product Category: Pomalyst/Imnovid
Overview
Performance
Product Category: Revlimid
Overview
Performance
Product Category: Thalomid
Overview
Performance
Product Category: Vidaza
Overview
Performance
Product Category: Other Revenue
Performance
Product Category: Product Revenue
Performance
Geographical Segment: International
Performance
Geographical Segment: The US
Performance
R&D Overview
Celgene Corp – SWOT Analysis
SWOT Analysis – Overview
Celgene Corp – Strengths
Celgene Corp – Weaknesses
Celgene Corp – Opportunities
Celgene Corp – Threats
Celgene Corp – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Celgene Corp, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 11, 2019: Celgene files for EU approval of ozanimod in relapsingremitting MS with US resubmission on track httpswww.firstwordpharma.comnode1628754Â $CELG
Mar 11, 2019: Celgene Submits Application to EMA for Ozanimod for the Treatment of RelapsingRemitting Multiple Sclerosis
Mar 04, 2019: Adagene announces a platform evaluation of the dynamic precision library with Celgene
Mar 01, 2019: BMS faces shareholder opposition to $74bn Celgene acquisition
Feb 26, 2019: Celgene Corporation Announces Key Regulatory Updates for REVLIMIDÂ in Lymphoma and Luspatercept in MDS and BetaThalassemia
Feb 25, 2019: Gainey McKenna & Egleston Announces that It Filed a Class Action Lawsuit Against Celgene Corporation (CELG) And Its Directors
Feb 20, 2019: Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene
Feb 05, 2019: Lyfebulb and Celgene announce call for innovation challenge applications to address unmet needs in multiple sclerosis
Feb 05, 2019: Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis
Jan 31, 2019: Celgene reports fourth quarter and full year 2018 operating and financial results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Celgene Corp, Key Facts
Celgene Corp, Key Employees
Celgene Corp, Key Employee Biographies
Celgene Corp, Major Products and Services
Celgene Corp, History
Celgene Corp, Other Locations
Celgene Corp, Subsidiaries
Celgene Corp, Key Competitors
Celgene Corp, Ratios based on current share price
Celgene Corp, Annual Ratios
Celgene Corp, Annual Ratios (Cont...1)
Celgene Corp, Annual Ratios (Cont...2)
Celgene Corp, Interim Ratios
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Celgene Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Celgene Corp, Performance Chart (2014 - 2018)
Celgene Corp, Ratio Charts
Celgene Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Celgene Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Celgene Corp (CELG):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The State Export-Import Bank of Ukraine:企業の戦略・SWOT・財務情報
    The State Export-Import Bank of Ukraine - Strategy, SWOT and Corporate Finance Report Summary The State Export-Import Bank of Ukraine - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Hansteen Holdings PLC:企業のM&A・事業提携・投資動向
    Hansteen Holdings PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hansteen Holdings PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Gebr. Heinemann SE & Co. KG:戦略・SWOT・企業財務分析
    Gebr. Heinemann SE & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Gebr. Heinemann SE & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • PanAtlantic Exploration Co:企業の戦略的SWOT分析
    PanAtlantic Exploration Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Groupe Le Duff S.A.(Foodservice):企業の戦略・SWOT・財務情報
    Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Groupe Le Duff S.A.(Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Sorrento Therapeutics Inc (SRNE):企業の財務・戦略的SWOT分析
    Sorrento Therapeutics Inc (SRNE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • AT&T Inc:戦略・SWOT・企業財務分析
    AT&T Inc - Strategy, SWOT and Corporate Finance Report Summary AT&T Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Qiagen NV (QIA):医療機器:M&Aディール及び事業提携情報
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify …
  • Global Partners LP (GLP):石油・ガス:M&Aディール及び事業提携情報
    Summary Global Partners LP (Global Partners) is a midstream logistics and marketing master limited partnership. It carries out purchasing, selling and logistics of transporting domestic and Canadian crude oil and other products by rail across its virtual pipeline from the mid-continent region of the …
  • PT Berau Coal Energy Tbk:企業の戦略・SWOT・財務情報
    PT Berau Coal Energy Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Berau Coal Energy Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • CVR Energy, Inc.:企業の戦略・SWOT・財務情報
    CVR Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary CVR Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Tyson Fresh Meats Inc:企業の戦略・SWOT・財務情報
    Tyson Fresh Meats Inc - Strategy, SWOT and Corporate Finance Report Summary Tyson Fresh Meats Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • China Power Clean Energy Development Co Ltd (0735):企業の財務・戦略的SWOT分析
    China Power Clean Energy Development Co Ltd (0735) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Celcuity Inc (CELC):企業の製品パイプライン分析
    Summary Celcuity Inc (Celcuity) is a cellular analysis company that develops companion diagnostic tests to identify new patient populations for targeted therapies. The company’s CELx signaling function diagnostic platform utilizes a patient’s living tumor cells to identify the specific abnormal cell …
  • ARMZ Uranium Holding Co:企業の戦略的SWOT分析
    ARMZ Uranium Holding Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Direct Flow Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Direct Flow Medical Inc (Direct Flow) is a medical device company that develops novel transcatheter heart valve technologies. The company provides transcatheter aortic valve implantation device without contrast. It also provides direct flow medical system, a technology for controlled and rel …
  • BFS Group Limited:企業の戦略・SWOT・財務情報
    BFS Group Limited - Strategy, SWOT and Corporate Finance Report Summary BFS Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • MedImmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune Ltd (MedImmune), formerly Cambridge Antibody Technology Ltd, is a subsidiary of AstraZeneca Plc, is a research and development company that develops and commercializes small molecule and biologic prescription medicines for the prevention of respiratory tract disease caused by respi …
  • Philippine National Bank
    Philippine National Bank - Strategy, SWOT and Corporate Finance Report Summary Philippine National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Powszechny Zaklad Ubezpieczen Group:企業の戦略・SWOT・財務情報
    Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report Summary Powszechny Zaklad Ubezpieczen Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆